胚胎着床前基因检测市场规模、份额和成长分析（按检测类型、技术、类别、最终用户和地区划分）—2026-2033年产业预测

全球胚胎着床前基因检测市场规模预计到 2024 年将达到 9.4331 亿美元，从 2025 年的 10.1406 亿美元增长到 2033 年的 18.0856 亿美元，在预测期（2026-2033 年）内复合年增长率为 7.5%。

全球胚胎着床前遗传学检测市场正经历显着成长，其主要驱动因素包括遗传疾病和不孕症发病率的上升、基因筛检技术的进步以及体外受精（IVF）基础设施的完善。遗传和染色体异常的日益普遍，以及久坐不动的生活方式和环境因素导致的不孕症发病率上升，都推动了对IVF及相关检测的需求。胚胎着床前遗传学检测对于减少IVF週期数、提高成功率至关重要。公众对遗传疾病、流产风险和孕产妇健康的日益关注，以及政府支持生殖健康的倡议，进一步推动了市场扩张。然而，高昂的检测成本、伦理困境、熟练专业人员短缺以及临床结果的不确定性等挑战，可能会阻碍未来的市场渗透。

全球胚胎着床前基因检测市场驱动因素

全球试管婴儿中心、生育诊所和专业诊断检查室数量的不断增长，推动了对这些服务的需求，并显着促进了全球胚胎胚胎着床前遗传学检测市场的发展。此外，尤其是在新兴经济体，对生殖健康基础设施的大量投资也为胚胎胚胎着床前遗传学检测服务提供者创造了新的机会。为满足日益增长的对先进生殖技术和基因筛检方法的需求，以改善患者预后和提高怀孕成功率，全球生育服务基础设施的扩张在塑造市场积极前景方面发挥关键作用。

限制全球胚胎着床前基因检测市场的因素

由于这些先进技术成本高昂，全球胚胎着床前遗传学检测市场面临严峻挑战。这些费用显着增加了体外受精（IVF）的整体成本。沉重的经济负担可能会阻碍经济条件有限的夫妻选择这项治疗方案。导致成本增加的因素包括这​​些检测所需的复杂技术、必要的实验室基础设施和专业知识。此外，缺乏保险覆盖也加剧了这个问题，使得中低收入者难以获得胚胎胚胎着床前遗传学检测，进一步限制了其普及性和可及性。

全球胚胎着床前基因检测市场趋势

全球胚胎着床前遗传学检测市场正经历着向非侵入性遗传学检测方法的重大转变，这主要得益于人们对微创手术日益增长的偏好。利用废弃胚胎培养基进行无细胞DNA分析的创新技术正在不断发展，使得无需直接采集胚胎细胞即可进行全面的遗传学检测。这项进步不仅最大限度地减少了对胚胎的潜在损伤，还提高了安全性和有效性，使非侵入性技术成为准父母的首选。随着人们对这些优势的认识不断加深，对更安全的遗传学检测方法的需求预计将塑造未来市场格局。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管环境

全球胚胎着床前基因检测市场规模（按检测类型和复合年增长率划分）（2026-2033 年）

• 胚胎着床前遗传学诊断（PGD）
• 胚胎着床前遗传学筛检（PGS）/非整倍筛检
• HLA型检测/胚胎配对
• 其他的

全球胚胎着床前基因检测市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 次世代定序（NGS）
• 聚合酵素链锁反应（PCR）
• 萤光原位杂合反应（FISH）
• 比较基因组杂合反应/微阵列
• 单核苷酸多态性（SNP）和基于人工智慧的平台

全球胚胎着床前基因检测市场规模（按类别划分）及复合年增长率（2026-2033 年）

• 试剂和耗材
• 设备/平台
• 软体和生物资讯学服务

全球胚胎着床前基因检测市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 不孕症诊所/试管婴儿中心
• 医院和辅助生殖技术（ART）中心
• 诊断检查室

全球胚胎着床前基因检测市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Illumina Inc.
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc.
• CooperSurgical Inc.
• Abbott Laboratories
• Natera Inc.
• Genea Limited
• Roche Holding AG
• Agilent Technologies Inc.
• Labcorp Holdings Inc.
• Invitae Corp.
• Oxford Gene Technology IP
• Yikon Genomics
• Bioarray SL
• Genesis Genetics
• Fulgent Genetics
• Igenomix
• Vitrolife AB
• MedGenome Labs
• CombiMatrix Corporation

结论与建议

Global Preimplantation Genetic Testing Market size was valued at USD 943.31 Million in 2024 and is poised to grow from USD 1014.06 Million in 2025 to USD 1808.56 Million by 2033, growing at a CAGR of 7.5% during the forecast period (2026-2033).

The global market for preimplantation genetic testing is experiencing significant growth driven by an increase in genetic disorders and infertility rates, coupled with advancements in genetic screening technology and enhanced IVF infrastructure. The prevalence of genetic and chromosomal abnormalities, alongside rising infertility stemming from sedentary habits and environmental factors, fuels the demand for IVF and associated testing. Preimplantation genetic testing is vital in minimizing IVF cycle numbers while boosting success rates. Growing public awareness about genetic conditions, miscarriage risks, and maternal health, along with government initiatives supporting reproductive health, further bolster market expansion. However, challenges like high procedure costs, ethical dilemmas, a shortage of skilled professionals, and uncertainties surrounding clinical outcomes may hinder market penetration moving forward.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Preimplantation Genetic Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Preimplantation Genetic Testing Market Segments Analysis

Global Preimplantation Genetic Testing Market is segmented by Test Type, Technology, Category, End-User and region. Based on Test Type, the market is segmented into Preimplantation Genetic Diagnosis (PGD), Preimplantation Genetic Screening (PGS) / Aneuploidy Screening, HLA Typing / Embryo Matching and Others. Based on Technology, the market is segmented into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Comparative Genomic Hybridization / Microarray and Single-Nucleotide Polymorphism (SNP) & AI-based Platforms. Based on Category, the market is segmented into Reagents & Consumables, Instruments / Platforms and Software & Bioinformatics Services. Based on End-User, the market is segmented into Fertility Clinics / IVF Centres, Hospitals & Assisted Reproductive Technology (ART) Centres and Diagnostic Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Preimplantation Genetic Testing Market

The global preimplantation genetic testing market is being significantly driven by the growing number of IVF centers, fertility clinics, and specialized diagnostic laboratories worldwide, which are enhancing the demand for these services. Additionally, substantial investments in reproductive healthcare infrastructure, particularly in emerging economies, are generating fresh opportunities for providers of preimplantation genetic testing. This expansion of fertility service infrastructure on a global scale is playing a crucial role in shaping the positive outlook for the market, as it accommodates the increasing need for advanced reproductive technologies and genetic screening methods aimed at improving patient outcomes and ensuring successful pregnancies.

Restraints in the Global Preimplantation Genetic Testing Market

The Global Preimplantation Genetic Testing market faces significant challenges due to the high costs associated with these advanced procedures, which significantly increase the overall expense of the in vitro fertilization (IVF) process. The substantial financial burden can deter couples with limited financial resources from pursuing this option. Factors contributing to the elevated costs include the sophisticated technology, necessary laboratory infrastructure, and specialized expertise required for these tests. Additionally, the absence of reimbursement options exacerbates the situation, rendering preimplantation genetic testing largely unattainable for individuals in lower- and middle-income regions, further limiting its adoption and accessibility.

Market Trends of the Global Preimplantation Genetic Testing Market

The Global Preimplantation Genetic Testing market is witnessing a significant shift toward non-invasive genetic testing approaches, propelled by an increasing preference for minimally invasive procedures. Innovations in the analysis of cell-free DNA from spent embryo culture media are gaining traction, allowing for comprehensive genetic testing without the need for direct embryo cell extraction. This advancement not only minimizes potential damage to embryos but also enhances safety and efficiency, positioning non-invasive techniques as a favorable option for prospective parents. As awareness of these benefits spreads, the demand for safer genetic testing methods is expected to shape the future landscape of the market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Preimplantation Genetic Testing Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Preimplantation Genetic Diagnosis (PGD)
• Preimplantation Genetic Screening (PGS) / Aneuploidy Screening
• HLA Typing / Embryo Matching
• Others

Global Preimplantation Genetic Testing Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Fluorescence In-Situ Hybridization (FISH)
• Comparative Genomic Hybridization / Microarray
• Single-Nucleotide Polymorphism (SNP) & AI-based Platforms

Global Preimplantation Genetic Testing Market Size by Category & CAGR (2026-2033)

• Market Overview
• Reagents & Consumables
• Instruments / Platforms
• Software & Bioinformatics Services

Global Preimplantation Genetic Testing Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Fertility Clinics / IVF Centres
• Hospitals & Assisted Reproductive Technology (ART) Centres
• Diagnostic Laboratories

Global Preimplantation Genetic Testing Market Size & CAGR (2026-2033)

• North America (Test Type, Technology, Category, End-User)
  • US
  • Canada
• Europe (Test Type, Technology, Category, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Technology, Category, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Technology, Category, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Technology, Category, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CooperSurgical Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genea Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Holdings Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae Corp.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Gene Technology IP
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yikon Genomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioarray S.L.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genesis Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fulgent Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Igenomix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vitrolife AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MedGenome Labs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CombiMatrix Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations